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I: Introduction to Placental Malaria
Chigozie J. Uneke
Faculty of Clinical Medicine, Ebonyi State University, Nigeria
Placental malaria is one of the major features of malaria during pregnancy and has been
widely used as a standard indicator to characterize malaria infection in epidemiologic inves-
tigations. Although pathogenesis of placental malaria is only partially understood, placental
sequestration of Plasmodium falciparum results in the accumulation of parasitized erythro-
cytes in the intervillous space, infiltration by inflammatory cells, and release of pro-inflam-
matory mediators, which cause pathologic alterations that could impair materno-fetal
exchanges, often resulting in adverse pregnancy outcome. In this report, the impact of pla-
cental malaria on pregnancy and perinatal outcome is reviewed using data from studies con-
ducted in sub-Saharan Africa. Generally, placental malaria was associated with increased
risk of maternal anemia, HIV infection, and maternal mortality, with younger women and prim-
igravidae more likely to be affected. A variety of adverse perinatal outcomes, including low
birth weight, preterm delivery, intrauterine growth retardation, reduced fetal anthropometric
parameters, fetal anemia, congenital malaria, increased mother-to-child HIV transmission,
and perinatal mortality, were associated with placental malaria. There were, however, con-
flicting reports on whether the risk of these adverse perinatal outcomes associated with pla-
cental malaria were statistically significant. There is a clear need to strengthen the malaria
prevention and intervention measures for pregnant women in sub-Saharan Africa.
INTRODUCTION
Malaria, which has been described as a
disease of poverty and underdevelopment,
remains a complex and overwhelming
health problem, with 300 to 500 million
cases and 2 to 3 million deaths per year [1].
About 90 percent of all deaths attributable
to malaria occur in sub-SaharanAfrica [1],
and two factors are largely responsible.
First, the majority of infections in this re-
gion are caused by Plasmodium falci-
parum, the most dangerous of the four
human malaria parasites; and second, the
most effective malaria vector — the mos-
quito Anopheles Gambiae — is the most
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cult to control [2,3]. In areas where malaria
is highly endemic, a protective semi-immu-
nity against P. falciparum is acquired during
the first 10 to 15 years of life, and the major-
ity of malaria-related morbidity and mortal-
ity occur in young children [4]. However, in
contrast with low malaria prevalence in
adults, pregnant women in endemic areas
are highly susceptible to malaria, and both
the frequency and the severity of disease are
higher in pregnant women [5]. In pregnancy,
there is a transient depression of cell-medi-
ated immunity that allows fetal allograft re-
tention but also interferes with resistance to
various infectious diseases [6]. Furthermore,
cellular immune responses to P. falciparum
antigens are depressed in pregnant women
[7,8].
Malaria during pregnancy is therefore a
serious problem in sub-Saharan Africa, af-
fecting an estimated 24 million pregnant
women annually [9].Although P. falciparum
infection in pregnancy is usually asympto-
matic, it often contributes to adverse perina-
tal outcomes with a high risk for infant
death, particularly in areas of lower malaria
endemicity [9]. Pregnancies in women liv-
ing in malaria endemic regions are associ-
ated with a high frequency and density of P.
falciparum parasitemia, with high rates of
maternal morbidity, including fever and se-
vere anemia, abortion, and placental malaria
[5,9]. Each year, between 75,000 and
200,000 infant deaths are attributed to
malaria infection in pregnancy globally
[6,10].
Despite the public health importance of
placental malaria, its impact on pregnancy
outcome in sub-SaharanAfrica has not been
comprehensively reviewed. In this three-
section report, an attempt was made to com-
prehensively review data from studies
conducted in sub-SaharanAfrica that inves-
tigated association between placental
malaria and a variety of adverse perinatal
and maternal outcomes. Searches in Med-
line/PubMed and in bibliographies of rele-
vant articles were used to collect articles for
review. In this section of the report, the diag-
nosis and pathologic features of placental
malaria will be reviewed. In the following
two sections, the known effects of malaria
infection in pregnancy on the fetus and the
mother will be comprehensively reviewed.
CHARACTERISTICS OF MALARIA-
INFECTED PLACENTA
The placenta is a complex, sophisti-
cated organ with several important functions
throughout gestation, with the primary pur-
pose of providing sustenance for the devel-
oping fetus. The placenta is also a site for P.
falciparum sequestration. Many hypotheses,
based on a systemic or local failure of the
immunological response to malaria, have
been proposed to explain the “preference”
of the parasites for replication in the pla-
centa; some have been reviewed elsewhere
[11]. At term, the placenta is usually a cir-
cular-shaped structure measuring approxi-
mately 20 cm in diameter and 2.5 cm in
thickness. The fetal portion of the placenta
consists of the chorionic plate and its villi
and the peripheral trophoblastic shell that
surrounds the intervillous space and covers
the maternal tissue. Anchoring villi contact
the decidua basalis. The decidua basalis
(maternal portion of the placenta) rests on
the stratum basalis and is characterized by
large, polyhedral pale blue stromal (decidua)
cells [12,13].
The placental sequestration of P. falci-
parum (placental malaria) results in the ac-
cumulation of parasitized erythrocytes in the
intervillous space, infiltration by inflamma-
tory cells, and release of pro-inflammatory
mediators [12], which cause pathologic al-
terations [13-15]. Histologically, placental
malaria is characterized by the presence of
intervillous parasites and leukocytes, malar-
ial pigment within macrophages, fibrin de-
posits and trophoblasts, proliferation of
cytotrophoblastic cells, and thickening of
the trophoblastic basement membrane
[11,14]. In a study conducted in Haut-
Ogooue, Gabon, malarial brown pigment
was observed in all cases of placental
malaria examined; it was characterized by
ultrastructural features and occurred in
perivillous deposits of fibrinoid, in
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[13]. Excessive perivillous fibrinoid de-
posits were a constant histologic finding and
were usually associated with syncytiotro-
phoblastic necrosis or ultrastructural dam-
age, such as partial microvilli loss,
filamentous material accumulation in intra-
cytoplasmic vacuoles, and “podocytelike”
cytoplasmic projections on the basal surface
[13]. It is at these sites that the trophoblastic
basal lamina was usually thickened.
In the Gambia study, the deposition of
malaria pigment in circulating cells was as-
sociated with active infection. Pigment in
fibrin and fibrinoid necrosis of chorionic
villi were features of active chronic infec-
tions; thickening of the trophoblast base-
ment membrane occurred in all infection
categories [16]. Despite increased under-
standing of the placental malaria pathology,
the exact mechanisms leading to placental
changes impairment of materno-fetal ex-
change are not completely understood.
However, it has been suggested the parasites
are unlikely to be directly responsible for the
placental pathology. Rather, leucocytes,
through the production of non-chemotactic
cytokines, might be associated with the
thickening of the trophoblastic basement
membrane and might cause mechanical
blockage of placental oxygen and nutrient
transport [11]. The high frequency of ad-
verse perinatal outcomes, including, but not
restricted to, premature, hypotrophic
neonates, and stillbirths in the malarial pop-
ulation, has been linked to the intervillous
macrophages, which decrease the maternal
blood output, and perivillous excess of fib-
rin, which reduces the materno-fetal ex-
changes [17]. A deeper understanding of
pathological mechanisms involved in pla-
cental malaria is vital in the design of effec-
tive protective interventions among pregnant
women in malaria endemic areas.
DIAGNOSING PLACENTAL
MALARIA
The sequestration of malaria parasites
in the placenta is one of the major features of
malaria infection during pregnancy. In semi-
immune women (i.e., those residing in areas
of unstable malaria transmission), the pro-
portion of parasitized erythrocytes is often
higher in the placenta than in peripheral
blood [18].Additionally, placental infection
may be detected in the absence of peripheral
blood parasitemia and may persist after ini-
tiation of antimalarial treatment [19].
Because not all malaria-exposed preg-
nant women in areas of malaria endemicity
suffer from placental malaria and its serious
consequences, a number of studies have as-
sessed the prevalence and risk factors of pla-
cental malaria in sub-Saharan Africa, while
others have attempted to elucidate protective
immune responses against placental infec-
tion and/or immune pathogenesis. However,
results from the various studies are often dis-
cordant, due in part to different techniques
of sample collection and analysis in different
studies, based on the differences in the def-
inition of placental malaria [20]. Some stud-
ies based their definition on the presence of
malaria parasite and/or pigments in blood
smears from placental blood [21,22,23].
Others based their definition on histological
findings [21,24-26], while yet others based
their definition on the use of histidine-rich-
protein-2 (HRP2) capture test [22,27-29]
and polymerase chain reaction (PCR)
[22,29-31]. In various parts of sub-Saharan
Africa, placental malaria prevalence rates
ranging from 9.5 percent to 37.1 percent
were obtained by placental blood smear mi-
croscopy, 35 percent to 75.5 percent by pla-
cental histological examination, 41 percent
to 43.1 percent by HRP2, and 51 percent to
59 percent by PCR [21,22,24,29,32].
It is pertinent to state that most studies
in sub-Saharan Africa relied on the results
of the placental smear, the sensitivity of
which is low compared with placental
histopathology. Using a more reliable
method of assessing placental infection,
such as the histopathologic examination,
might have changed the results [33,34]. Al-
though microscopy with placental blood is
less sensitive than placental histology, it is
considerably more sensitive in the diagnosis
of maternal malaria than peripheral blood
smears [35]. For instance, in southern
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fected delivering women were asympto-
matic, and microscopy of thick films from
peripheral blood missed more current infec-
tions than it detected, with roughly half of
the women with microscopically proven pla-
cental parasitemia having a P. falciparum
negative peripheral blood film [22]. In Blan-
tyre, Malawi, blood smear microscopically
detectable P. falciparum peripheral and pla-
cental infection was more common in
women with their first and second pregnan-
cies than in multigravid women, but neither
infection detected by histology only nor in-
cidences of past infection differed with gra-
vidity, and similar numbers of women were
uninfected [35].
Placental histology is therefore consid-
ered the “gold standard” of malaria diagno-
sis in pregnancy for epidemiological or
biological study purposes, because it can
show signs of active infection (presence of
infected erythrocytes in the intervillous
space), past or chronic infection (malarial
pigment), or both [33]. However, due to lim-
ited technical expertise, such testing is rarely
available in endemic areas; examination of
thick films of blood samples obtained by
placental incision is comparatively easier
[22]. As compared to histology, sensitivity
and specificity of this method have been re-
ported to be 76 percent and 99 percent, re-
spectively, and thus is in the range of blood
film microscopy produced by scraping the
wall of placental incisions or by spinning
down erythrocyte pellets from biopsy wash-
ings [35]. Although placental hemozoin is
described as the clinically most relevant
marker of infection, detection of hemozoin
on placental thick blood films is likely influ-
enced by this difference in sensitivity and
also neglects pigment deposition in placental
structures [22]. It has been argued that stag-
ing placental infection based on placental
thick blood films findings — although de-
duced from the histological classification
[36] is not fully comparable to histology and
needs further evaluation [22].
The comparisons of microscopy, HRP2
(or other rapid diagnostic tests (RDTs†)), and
PCR in placental malaria diagnosis are chal-
lenging to interpret because they detect in-
fection in different ways: microscopy de-
tects viable whole parasites in red blood
cells, HRP2 detects specific parasite pro-
teins, and PCR detects parasite DNA [29].
Although the HRP2 and PCR are able to de-
tect parasite debris present in the blood
when viable parasites may be sequestered in
the placenta or persist at very low densities,
both parasite proteins and DNA can be de-
tected after successful treatment, making the
results of HRP2 and PCR potentially con-
fusing in a clinical setting [29]. PCR assays
also detect low-level infections that produce
no major fetal impairment; however, some
studies have shown that submicroscopic in-
fections detected by PCR are associated with
mild maternal anemia and inflammation,
and submicroscopic infections detected by
rapid diagnostic test are associated with ma-
ternal anemia and low birth weight
[22,37,38]. A better understanding of the
clinical and epidemiological relevance of
detection techniques is imperative for proper
interpretation.
PLACENTAL MALARIA, MATERNAL
HEALTH, AND PUBLIC HEALTH
Plasmodium falciparum infections of
the placenta remain a major medical chal-
lenge among pregnant women in sub-Saha-
ranAfrica.Anumber of factors influence the
prevalence of placental malaria in pregnant
women, including maternal age, gravidity,
use of prophylaxis, nutrition, host genetics,
and level of antiparasite immunity, as well
as parasite genetics and transmission rates
[23]. Maternal anemia has been shown to be
one of the major complications of placental
malaria in sub-Saharan Africa. The mecha-
nisms by which malaria causes anemia are
fairly well understood.The pathophysiology
of malaria-associated anemia is multifacto-
rial.The most likely mechanisms include (1)
hemolysis or the direct destruction of para-
sitized red blood cells that occurs both in-
travascularly and by sequestration in the
microcirculation, mainly in the spleen; (2)
specific/nonspecific immune responses,
whereby red cell survival is shortened; (3)
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which depresses erythropoiesis, inhibits
reticulocyte release, and prematurely de-
structs red cells during maturation in the
bone marrow; and (4) hypersplenism asso-
ciated with a reduction in all three blood cell
series, that is, causing not only anemia but
also thrombocytopenia and leucopenia
[39,40].
The relationship between maternal ane-
mia with obstetric factors however, is not
fully understood, and thus, evaluating the
link between malaria, obstetric disorders,
and maternal death has been recommended
[41].There have been efforts to quantify the
contribution of malaria to maternal morbid-
ity and mortality with the expectation this
would provide the evidence necessary to im-
prove the effectiveness of advocacy to incor-
porate malaria prevention strategies in Safe
Motherhood Programs [42,43]. The effects
of placental malaria on maternal health can
better be understood when considered in re-
lation with various maternal parameters, in-
cluding maternal age, parity, peripheral
malaria infection, anemia, and HIV infec-
tion.
MATERNAL HEALTH AND MALARIA
Increased Morbidity and Mortality
Although pregnant women in malaria
endemic areas have higher rates of para-
sitemia and parasite density compared with
non-pregnant women, infection is largely
asymptomatic because some degree of pre-
existing immunity is retained during preg-
nancy [44]. However, even malaria-immune
women (i.e., those who have evolved some
level of immunity against severe infection
as a result of long residence in areas of sta-
ble malaria transmission) are susceptible to
placental malaria [23,24]. Because so many
parasites become sequestered within the pla-
centa, peripheral blood smears often fail to
detect evidence of infection. The resulting
lack of appropriate or timely treatment may
lead to adverse pregnancy outcome, includ-
ing severe anemia, which is the main mater-
nal consequence of malaria and can be
deadly [44]. Apart from anemia, malaria
may contribute to maternal mortality by in-
creasing the risk and severity of obstetric
conditions such as pre-eclampsia/eclampsia
and postpartum hemorrhage by as much as
50 percent [45,46].
Maternal anemia
Anemia is the most common conse-
quence of P. falciparum malariainfection.In
sub-Saharan Africa, it is estimated that be-
tween200,000and500,000pregnantwomen
develop severe anemia as a result of malaria
[9], and P. falciparum malaria in pregnancy
istheprimarycauseofupto10,000maternal
anemia-related deaths in sub-SaharanAfrica
annually [43,47]. However, there have been
conflictingreportsfrompartsofsub-Saharan
Africa on the relationship between placental
malaria and maternal anemia. An earlier re-
port from the Ubangi district of Zaire noted
thatmalariousplacentashadnoconsistentre-
lationship to maternal anemia [48]. In other
studies, maternal anemia and placental
malaria were associated in all gravidity and
age groups, with maternal anemia higher
among women with placental malaria than
thosewithoutplacentalmalaria(bygravidity,
prevalence ranged from 28.8 percent to 31.6
percentforpositivecasesand15.3percentto
16.7 percent for negative cases; by age,
prevalence ranged from 26.5 percent to 31.8
percentforpositivecasesand15.3percentto
17.7 percent for negative cases) [23]. The
reason for this variation is not clear, but it
may be connected to the complex and multi-
factorial etiology of anemia in pregnancy in
sub-SaharanAfrica [39].
In most areas of malaria endemicity,
many other causes of anemia have been
identified, including both nutritional (iron,
folate and protein deficiency) and non-nu-
tritional (hookworm or HIV infection, he-
moglobinopathy) factors, [40,49]. Since
many of these causes of anemia occur con-
currently in pregnancy and no unique hall-
marks of malaria-driven anemia have been
identified, it is difficult to evaluate the con-
tribution made to anemia in pregnancy by
placental malaria infection [50].Apart from
its significant contribution to maternal mor-
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anemia in pregnancy is a risk factor for in-
fant iron deficiency anemia [51] that, if left
uncorrected, can be associated with adverse
behavioral and cognitive development [52].
Severe anemia in pregnancy is an important
direct and indirect cause of maternal death.
During pregnancy, severe anemia may re-
sult in circulatory changes associated with
an increased risk of heart failure and acute
onset of anemia due to rapid cardiac decom-
pensation and decreases in hemoglobin
(Hb) concentration to < 80g/L. Such
changes can result in the failure of compen-
satory mechanisms, accumulation of lactic
acid and breathlessness at rest [53]. Further-
more, during labor, women with severe ane-
mia are less able to endure even moderate
blood loss and, as a consequence, are at a
higher risk of requiring a blood transfusion
during delivery [40]. For the fetus, severe
maternal anemia may result in intrauterine
growth retardation, still birth, and low birth
weight [54-57]. The mechanism of malaria-
driven anemia can be described in associa-
tion with iron status in pregnancy. The iron
status in pregnancy is affected by malaria
parasites, which influence the anemia ob-
served in pregnancy. P. falciparum may af-
fect iron status through (1) reducing
intestinal iron absorption, (2) sequestrating
iron within the malarial pigment hemeo-
zoin, (3) consuming iron for its own metab-
olism, (4) promoting/stimulating the
mobilization of iron to body stores, and (5)
releasing iron into the circulation during in-
travascular hemolysis [39,40].
Maternal Age and Malaria Infection
A number of studies conducted in sub-
Saharan Africa have reported a significant
association between maternal age and
malaria infection during pregnancy [58-61].
In a study conducted in Blantyre, Malawi,
after stratifying by gravidity, associations
between age and parasite prevalence were
stronger than those between gravidity and
prevalence after stratifying by age [59].
Under conditions of low-to-moderate trans-
mission, pregnancy-specific immunity is
slow to develop, and age-related immunity
may influence malaria prevalence in child-
bearing years [59].
Studies have shown that young women
of child-bearing age may be more suscepti-
ble than older women to malaria because
they are still in the process of acquiring nat-
ural immunity to malaria [62-64]. In
Cameroon, age was a major risk factor for
placental malaria, with younger first-time
mothers more likely to have placental
malaria [23]. Similarly, in Zaire, mothers
with malarious placentas were younger
(mean age 24) than mothers with non-malar-
ious placentas (mean age 29) [48]. It was
suggested that development of pregnancy-
associated immunity, i.e., production of an-
tibodies that inhibit the adherence of
placental parasites to chondroitin sulfate A
(CSA), may be very important in women
less than 25 years of age who have lower
levels of acquired immunity (through less
frequency of exposure to the bites of P. fal-
ciparum infected mosquitoes) than in older
women who may have obtained adequate
immunity following repeated exposures and
thus are less dependent on anticytoadherent
antibodies [23]. However, it is important to
state that in malarious areas, pregnancy-as-
sociated and age-dependent immunity to
placental malaria may be influenced by host
or environmental factors.
PARITY AND HEALTH
The relationship between placental
malaria and parity is well established. Many
recent studies have found the prevalence to
be higher in primigravidae than multigravi-
dae, and in these studies, results are con-
trolled for age [21,23,65,66]. These
observations are consistent with the findings
of earlier studies in malaria-endemic re-
gions, where, among several factors, parity
independently influenced the placental
malaria prevalence rate, with primigravidae
having a two- to four-fold increased risk of
placental malaria compared to multigravidae
[5,67,68]. In Gambia, it was observed that
the severest form of placental parasitization
occurred in a higher proportion of the prim-
igravidae than in the multigravidae [21].
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tal malaria was associated with hypertension
in young first-time mothers with histologic
features of chronic disease but not related to
hypertension in older or multigravid women.
Similarly, placental malaria was associated
with elevated levels of placentally derived
soluble vascular endothelial growth factor
receptor 1 (sVEGFR1) in first-time mothers
but not in multigravid mothers with age
being controlled [69]. sVEGFR1 may cause
systemic endothelial dysfunction by binding
to and sequestering free serum vascular en-
dothelial growth factor (VEGF) and placen-
tal growth factor [70,71], which is
associated with higher risk adverse perinatal
outcome among primigravidae with as much
risk as up to 25 percent [70]. The exact rea-
son why primigravidae are more susceptible
to placental malaria and suffer from its con-
sequences more than multigravidae is yet to
be fully elucidated. However, a common ex-
planation is that pregnancy is associated
with a decrease in immunity, which is more
pronounced in primigravidae than in multi-
gravidae and may be associated with age
[72]. Immunological studies have shown
that this increase in susceptibility could be
related to the property of parasitized erythro-
cytes to adhere to chondroitin sulfate A
(CSA) expressed by the syncytiotrophoblast
of the placenta [73,74]. Thus, the placenta
may select for the CSA-binding P. falci-
parum phenotype, putting primigravidae
with no previous exposure to this parasite
form at increased risk for developing placen-
tal malaria. The decreasing susceptibility to
pregnancy-associated malaria with increas-
ing parity is reflected in the acquisition of
antibodies specific to parasites’variant anti-
gens expressed on the surface of infected
erythrocytes [75].Another possible explana-
tion for this parity-related susceptibility is
given by the findings of Duffy and Fried
[76], who showed that multigravid mothers
develop malaria antibodies that block adhe-
sion of parasites to CSAreceptors in the pla-
centae in subsequent pregnancies. More
studies using both immunological and mo-
lecular biological tools are urgently needed
to properly elucidate this parity-related sus-
ceptibility to placental malaria. However,
since pregnant women in malarious areas
produce antibodies that specifically recog-
nize CSA-binding P. falciparum, this could
form a basis for the development of a vac-
cine to protect pregnant women against pla-
cental malaria.
PERIPHERAL MALARIA INFECTION
The relationship between maternal pe-
ripheral parasitemia and placental malaria
has been evaluated in some parts of sub-Sa-
haran Africa. There are no rigorous studies
on whether placental infection reflects the
existence of peripheral infection over a short
period preceding the delivery or whether it is
related to infection during pregnancy. Two
studies have shown some relation between
a late infection (i.e., infection acquired late
in pregnancy) and positivity of placental
smears or presence of pigment [77,78], but it
has been argued that a single measure can
hardly reflect the entire history of infection
during pregnancy. In one study, the occur-
rence of peripheral parasitemia at the begin-
ning and at the end of pregnancy was
significantly related to placental infection,
whereas peripheral parasitemia in the middle
of pregnancy was not [72]. This suggests
that a peripheral parasitemia at the begin-
ning of pregnancy may persist within the
placenta throughout gestation, with possibly
more severe consequences for the placenta
and the newborn than an infection acquired
later in pregnancy.
Other studies have shown that periph-
eral infection confers a five-fold increased
risk for placental malaria, thus confirming
the importance of late maternal infections
[79].Although maternal peripheral infection
toward the end of pregnancy (post seven
months) predisposes the woman to placental
malaria, risk of placental infection is greater
if peripheral infection occurs at the begin-
ning of pregnancy [5]. In Malawi, placental
infection was more frequent in women who
were infected at enrollment (i.e., during the
first trimester of pregnancy) in the study
than those who were not infected at enroll-
ment [79]. Early peripheral infection during
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risk factor for placental infection, due to
lower immune protection at the beginning of
pregnancy. Nevertheless, susceptibility may
be correlated to high exposure to malaria,
and repeated episodes of parasitemia, as
well as the interplay between several other
factors, should form the basis for further in-
vestigations.
PUBLIC HEALTH CONSIDERATIONS
Despite considerable improvement in
healthcaredeliveryservicesintheAfricancon-
tinent, the control of malaria in pregnant
African women, one of several child survival
strategies applied through antenatal care, con-
tinuestobeparticularlychallenging.Prevention
andcontrolrecommendationsfortypicalareas
of high P. falciparum transmission have pro-
moted the use of antimalarial chemoprophy-
laxis to prevent placental infection and its
associated adverse perinatal outcome. This
confirmspriorfindings[80].Otherrandomized
trialsshowaprotectiveeffectofprophylaxison
placental infection or peripheral parasitemia
[79,81,82].However,persistentlylowprogram




doxine pyremethamine, proguanil, and
pyremethamine, while the curative ones in-
clude artesunate, chloroquine, and amodi-
aquine. These drugs are relatively safe in
pregnancy and are widely used in malariouos
areasof sub-SaharanAfrica[84].
In the face of the mounting evidence of
the relative failure of many traditional anti-
malarial drugs, particularly chloroquine, the
WHO has put forward new guidelines for
combating and preventing malaria during
pregnancy [58,84]. The guidelines recom-
mend that women living in high transmis-
sion areas of Africa receive intermittent
preventive treatment (IPT) with an effective
antimalarial agent such as sulfadoxine-
pyrimethamine (SP) at scheduled antenatal
visits, and all pregnant women in targeted
areas should undergo at least two sessions
of IPT after first fetal movements (i.e., be-
tween 20 to 35 weeks) [84]. Unfortunately,
the implementation of the WHO guidelines
has been burdened by the notorious prob-
lems complicating health service delivery in
the developing world, particularly in the
African continent, namely, the logistical
challenges of reaching remote regions, re-
source scarcity, lack of infrastructure, inad-
equate treatment, continuing poverty, and
armed conflict.
It is well established that women in
Africa use prenatal care extensively when it
is available and accessible.This opportunity
must be used to implement evidence-based
actions with appropriate and realistic goals.
There is an urgent need to improve access of
rural women to antenatal clinic services in
sub-Saharan Africa, either through increas-
ing the number of rural health centers or by
establishing functioning outreach services.
The distribution of insecticide-treated bed
nets needs to become implemented on a
large scale.
Since pregnant women have increased
specific risks of complications from both
malaria and HIVinfection, the financial and
human resource constraints of health sys-
tems in countries most affected by malaria
and HIVand the shared determinants of vul-
nerability for both diseases indicate the need
for integration of preventive and curative
services for malaria and HIV. The health
systems that deliver these services must be
strengthened [55]. Reproductive health serv-
ices offer a critical opportunity for routine
provider-initiated HIV testing and counsel-
ing. They can provide follow-up care with
prevention of MTCT interventions accord-
ing to national policy for those who test pos-
itive, coupled with entry to antiretroviral
therapy programs for those sick and in need
of immediate therapy. These services need
to be strengthened to ensure the delivery of
the WHO-recommended antenatal care
schedule of four visits (focused antenatal
care), which includes a minimum package
of interventions for the prevention of both
malaria and HIV [85].
Studies in malarious regions have
demonstrated that substantial reductions in
maternal malaria, anemia, and low birth
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programs,includingtheuseofpreventivein-
termittent treatment, chemoprophylaxis, and
the use of insecticide-treated nets. In fact,
studies suggest that between 25 percent and
90 percent of these adverse events might be
prevented by full implementation of existing
interventions [9]. Interventions, therefore,
should also exist for maternal anemia (e.g.,
good nutrition, iron and folate supplementa-
tion,andhookwormtreatment)andforreduc-
tion of mother-to-infant HIV transmission
(e.g.,short-coursezidovudineornevirapine),
and such can be provided through antenatal
care programs [56,86-89]. Better application
of these malaria, anemia, and HIV interven-
tions could markedly reduce the infant mor-
tality burden of these diseases.
Finally, collaboration between scien-
tists, policy makers, and control programs
should be strengthened and community-
level research encouraged in order to guide
programs and monitor and evaluate markers
of success.
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